>> The announcement coincides with the publication of a patent application by the Patent Cooperation Treaty (PCT)
office regarding the use of monoclonal antibodies directed to the complement component properdin. <<
I've been wondering if the complement work would lead to a non-neuro program. Now we know why the stock took a dive yesterday.... investors upset with a lack of focus.
I am pleased..... yet another development program, and I've made my opinion of the utility of anti-complement approaches earlier in the thread. Humanized monoclonal...... OK, but a mention of Janssen, even a repeat of the last commentary, would have been nice.
Not counting Adcons other than -P, the company now has at least five development programs, one of which is in pivotal human trials and one of which has completed single-dose phase I. I suspect that the H(3) news has gotten better and better, and that Oesterling is making a grab for independent pharma. Given their structure and the current mood for M&A, I see nothing but upside from this for risk-loving investors.
Another program that addresses huge markets, this one competitive with ALXN, whatever TCEL is now called, and several other companies including pharmas. I'll need to check on the potential advantages of choosing properdin as a target. |
